| Delaware                                                     |   | 20-5894890                         |
|--------------------------------------------------------------|--------|------------------------------------|
| (Stateor Other Jurisdiction ofIncorporation or Organization) |   | (I.R.S.EmployerIdentification No.) |

| 400Connell Drive, Suite 5000, Berkeley Heights, NJ |   | 07922     |   |
|----------------------------------------------------|--------|-----------|--------|
| (Addressof Principal Executive Offices)            |   | (ZipCode) |   |

| Titleof each class            |   | Name ofeach exchange on which registered |
|-------------------------------|--------|------------------------------------------|
| CommonStock, $0.001 Par Value |   | NYSEAmerican LLC                         |

| Largeaccelerated filer ☐ | Acceleratedfiler ☐         |
|---------------------------------|-----------------------------------|
|                            |                              |
| Non-acceleratedfiler ☐   | Smallerreporting company ☒ |

| PARTIII |                                                                                          |   |
|---------|-----------------------------------------------------------------------------------------------|--------|
| Item10. | Directorsand Executive Officers and Corporate Governance.                                | 1      |
| Item11. | ExecutiveCompensation.                                                                        | 6      |
| Item12. | SecurityOwnership of Certain Beneficial Owners and Management and RelatedStockholder Matters. | 14     |
| Item13. | CertainRelationships and Related Transactions and DirectorIndependence.                       | 16     |
| Item14. | PrincipalAccountant Fees and Services.                                                        | 18     |
| PartIV  |                                                                                          |   |
| Item15. | Exhibitsand Financial Statement Schedules                                                     | 18     |

 

| Name                |   | Age |   | Director Since |   | Position(s) with CorMedix            |
|---------------------|--------|-----|--------|---------------------|--------|--------------------------------------|
| KhosoBaluch         |   | 60  |   | October 2016        |   | Director and Chief Executive Officer |
| JanetM. Dillione    |   | 58  |   | August 2015         |   | Director                             |
| Gary Gelbfish(1)    |   | 59  |   | August 2017         |   | Director                             |
| Myron Kaplan(2)     |   | 73  |   | April 2016          |   | Chairman of the Board                |
| MehmoodKhan         |   | 60  |   | June 2017           |   | Director                             |
| Steven Lefkowitz(3) |   | 62  |   | June 2017           |   | Director                             |

| Name          |   | Age |   |   | Position(s) with CorMedix                         |
|---------------|--------|-----|--------|--------|---------------------------------------------------|
| KhosoBaluch   |   | 60  |   |   | Chief Executive Officer                           |
| RobertCook    |   | 62  |   |   | Chief Financial Officer                           |
| JohnArmstrong |   | 73  |   |   | Executive Vice President for Technical Operations |

| Name                 |  Fees Earned($)  |  OptionAwards(1)(2) ($)  |  Restricted UnitsAwards(1)(3)($)  |   Total ($)  |
|----------------------|----------------------------|-----------------------------------------|---------------------------------------------|----------------------------------|
| JanetM. Dillione     |   30,000(4)      |   68,760                 |   34,400                     |   133,160         |
| Gary Gelbfish(5)     |   63,338(5)      |   20,775                 |   -                          |   84,113          |
| Michael W. George(6) |   14,670(4)      |   68,760                 |   27,400                     |   110,830         |
| MyronKaplan          |   27,052    |   68,760                 |   25,400                     |   121,212         |
| MehmoodKhan          |   14,895    |   25,500                 |   -                          |   40,395          |
| Steven Lefkowitz(7)  |   14,895    |   25,500                 |   -                          |   40,395          |
| Taunia Markvicka(8)  |   14,670    |   68,760                 |   30,400                     |   113,830         |
| Cora Tellez(9)       |   13,269(4)      |   68,760                 |   46,400                     |   128,429         |

| Nameand Principal Position  | Year   |  Salary($)      |  OptionAwards(1)($)  |  Restricted Stock Units Awards(1) ($)  |  Non-equityIncentive Plan Compensation($)  |   AllOther Compensation($)  |  Total($)         |
|-----------------------------|--------|---------------------------|--------------------------------|-------------------------------------------------------|------------------------------------------------------|--------------------------------------------|-----------------------------|
| Khoso Baluch(2)             | 2017   |   375,000  |   --            |   --                                   | (7)                                                  |   68,533(8)                      |  443,533               |
| ChiefExecutive Officer      | 2016   |   93,750   |   3,186,450     |   --                                   |   75,000                              |   39,574(8)                      |   3,394,774  |
| Robert W. Cook(3)           | 2017   |   320,385  |   455,945       |   --                                   | (7)                                                  |   24,273(9)                      |  800,603               |
| ChiefFinancial Officer      | 2016   |   --       |   --            |   --                                   |   --                                  |   --                        |   --         |
| John Armstrong(4)           | 2017   |   341,056(4)    |   167,020       |   78,604(4)                                 | (7)                                                  |  --                              |  586,680               |
| ExecutiveVice President for | 2016   |   335,400(4)    |   1,150,755     |   --                                   |   --                                  |   --                        |   1,486,155  |
| TechnicalOperations         |   |       |            |                                   |                                  |                        |         |
| Judith Abrams(5)            | 2017   |   346,733(5)    |   455,945       |   --                                   |   --                                  |   15,448(9)                      |   818,126    |
| ChiefMedical Officer        | 2016   |   --       |   --            |   --                                   |   --                                  |   --                        |   --         |
| James Altland(6)            | 2017   |   57,100(6)     |   --            |   --                                   |   --                                  |   --                        |   57,100     |
| InterimChief Financial      | 2016   |   244,485  |   --            |   --                                   |   --                                  |   --                        |   244,485    |
| Officer                     |   |       |            |                                   |                                  |                        |         |

| Name          |  Number of Shares Underlying Unexercised Options (#) –Exercisable  |  Number of Shares Underlying Unexercised Options (#) –Unexercisable  |  Option Exercise Price ($)  | Option Expiration Date |
|---------------|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------|------------------------|
| KhosoBaluch   |   312,500                                                            |   1,537,500                                                            |   2.52                 | 10/03/2026             |
| RobertW. Cook |   --                                                                 |   350,000                                                              |   1.69                 | 1/30/2027              |
| JohnArmstrong |   10,000                                                             |   --                                                                   |   1.52                 | 11/14/2024             |
|          |   15,000                                                             |   --                                                                   |   3.25                 | 7/28/2025              |
|          |   171,875                                                            |   28,125                                                               |   2.51                 | 3/08/2026              |
|          |   --                                                                 |   100,000                                                              |   2.18                 | 3/01/2027              |
| JudithAbrams  |   46,250                                                             |   --                                                                   |   1.69                 | 8/23/2018              |

| Name          |  Cash Payment($ per month) and(# of months paid)  |  Benefits($ per month) and(# of months paid)  |  Number of Options(# that would vest) and($ market value)(1)  |
|---------------|-------------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------------------|
| KhosoBaluch   |  $31,250                                          | 12mos.                                                  |  $2,564                                                       | 12mos. |   1,537,500  |  $-0-  |
| Robert W.Cook |  $29,167                                          | 9mos                                                    |  $2,755                                                       | 9 mos |   350,000  |  $-0-  |
| JohnArmstrong |  $25,833                                          | 9mos                                                    |  $--                                                          | 9 mos |   128,125  |  $-0-  |

| ● | eachperson known by us to own beneficially more than 5% of theoutstanding shares of our common stock;                                                            |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ● | eachdirector;                                                                                                                                                    |
| ● | each ofour executive officers named in the Summary Compensation Tablebelow (the “Named Executive Officers”) and our currentexecutive officers; and |
| ● | all ofour current directors and executive officers as agroup.                                                                                                    |

| Name andAddress of Beneficial Owner                            |  CommonStockBeneficially Owned (1)  |
|----------------------------------------------------------------|-----------------------------------------------|
|                                                           |  Shares                             |  %  |
| 5% or Greater Stockholders                                     |                                |     |
| Elliott Associates,L.P. (2)                                    |  8,614,866                               |   9.9% |
|                                                           |                           |      |
| Directors and Named Executive Officers:                        |                           |      |
| Khoso Baluch(3)                                                |   537,873                           |   *  |
| Robert Cook(4)                                                 |   148,333                      |   *  |
| John Armstrong(5)                                              |   237,299                      |   *  |
| ElizabethMasson                                                |   -                            |   -  |
| Janet M. Dillione(6)                                           |   292,409                      |   *  |
| Gary Gelbfish(7)                                               |   4,890,121                    |   5.8% |
| Myron Kaplan(8)                                                |   384,166                      |   *  |
| Mehmood Khan(9)                                                |   477,083                      |   *  |
| Steven Lefkowitz(10)                                           |   383,636                      |   *  |
| All executive officers and directors as agroup (9 persons)(11) |   7,350,920                    |   8.7% |
|                                                           |                           |      |
|  * Less than 1%                                      |

|         | (1)    | Based upon 81,786,902 shares ofour common stock outstanding on March 31, 2018 and, with respect toeach individual holder, rights to acquire our common stockexercisable within 60 days of March 31, 2018.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|--------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|    | (2)    | Due tothe Ownership Limitation (as defined below), Elliott Associates,L.P. (“Elliott Associates”) may be deemed thebeneficial owner of 8,614,866 shares of our common stock throughsecurities held by it and by Manchester Securities Corp., awholly-owned subsidiary of Elliott Associates(“Manchester”), and Elliott International, L.P.(“Elliott International”), the investment advisor ofwhich is an affiliate of the investment advisor of ElliottAssociates. Elliott Associates beneficially holds: (i) 2,833,470shares of our common stock held by Elliott International, (ii)1,333,398 shares of our common stock held by Elliott Associates,(iii) May 2013 warrants held by Manchester exercisable for 500,000shares of our common stock, (iv) 52,500 shares of our Series C-2non-voting convertible preferred stock held by Elliott Associatesconvertible into 525,000 shares of our common stock, (v) October2013 warrants held by Elliott Associates exercisable for 262,500shares of our common stock, (vi) 97,500 shares of our Series C-2non-voting convertible preferred stock held by ElliottInternational convertible into 975,000 shares of our common stock,(vii) October 2013 warrants held by Elliott Internationalexercisable for 487,500 shares of our common stock, (viii) 73,962shares of our Series D non-voting convertible preferred stock heldby Manchester convertible into 1,479,240 shares of our commonstock, (ix) March 2015 Warrants held by Manchester convertible into200,000 shares of our common stock, (x) May 2017 Series A warrantsheld by Elliott International convertible into 1,360,001 shares ofour common stock, (xi) May 2017 Series A warrants held by ElliottAssociates convertible into 640,000 shares of our common stock,(xii) May 2017 Series B warrants held by Elliott Internationalconvertible into 1,360,001 shares of our common stock, (xiii) May2017 Series B warrants held by Elliott Associates convertible into640,000 shares of our common stock, (xiv) 89,623 shares of ourSeries E non-voting convertible preferred stock held by Manchesterconvertible into 1,959,759 shares of our common stock, (xv) 1,360shares of our Series F non-voting convertible preferred stock heldby Elliott International convertible into 2,147,142 shares of ourcommon stock (subject to adjustment), (xvi) 640 shares of ourSeries F non-voting convertible preferred stock held by ElliottAssociates convertible into 1,010,419 shares of our common stock(subject to adjustment), (xvii) November 2017 warrants exercisablefor 384,103 shares of our common stock held by ElliottInternational, and (xviii) November 2017 warrants exercisable for180,755 shares of our common stock held by Elliott Associates (theMay 2013 warrants, the October 2013 warrants, the March 2015Warrants, the May 2017 Series A warrants, the May 2017 Series Bwarrants, the November 2017 warrants and all shares of preferredstock shall collectively be referred to herein as the“Convertible Securities”). However, in accordance withRule 13d-4 under the Exchange Act, the number of shares of ourcommon stock into which the Convertible Securities are convertibleor exercisable, as applicable, are limited pursuant to the terms ofthe Convertible Securities to that number of shares of our commonstock which would result in Elliott Associates having aggregatebeneficial ownership of, with respect to the May 2013 warrants, theOctober 2013 warrants, the March 2015 Warrants, the May 2017 SeriesA warrants, the May 2017 Series B warrants, the November 2017warrants, the Series C-2 preferred stock, the Series D preferredstock, the Series E preferred stock and the Series F preferredstock, 9.99% of the total issued and outstanding shares of ourcommon stock (the "Ownership Limitation"). Elliott Associatesdisclaims beneficial ownership of any and all shares of our commonstock issuable upon any conversion or exercise of the ConvertibleSecurities if such conversion or exercise would cause ElliottAssociates’ aggregate beneficial ownership to exceed orremain above the applicable Ownership Limitation (as is currentlythe case). Therefore, Elliott Associates disclaims beneficialownership of any shares of our common stock, issuable upon anyconversion or exercise of the May 2013 warrants, the October 2013warrants, the March 2015 Warrants, the May 2017 Series A warrants,the May 2017 Series B warrants, the November 2017 warrants, theSeries C-2 preferred stock, the Series D preferred stock, theSeries E preferred stock and the Series F preferred stock, whichconversion of exercise would be prohibited by the OwnershipLimitation. The business address of Elliott Associates is 40 West57th Street, 30th Floor, New York, New York 10019. Based solely oninformation contained in a Schedule 13D filed with the SEC onNovember 13, 2017 by Elliott Associates and other information knownto us.  |
|         |   |
|    | (3)    | Consists of (i) 225,373 shares ofour common stock, and (ii) 312,500 shares of our common stockissuable upon exercise of stock options.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|         | (4)    | Consists of (i) 102,083 shares ofour common stock, and (ii) 46,250 shares of our common stockissuable upon exercise of stock options.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|    | (5)    | Consists of (i) 38,861 shares ofour common stock, and (ii) 198,438 shares of our common stockissuable upon exercise of stock options.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|    | (6)    | Consists of (i) 107,409 shares ofour common stock, and (ii) 185,000 shares of our common stockissuable upon exercise of stock options. Does not include anaggregate of 85,119 shares of our common stock that were deferredas director fee compensation and that are not issuable until afterthe individual’s cessation of service with ourBoard.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|    | (7)    | Consists of (i) 2,115,121 sharesof our common stock, (ii) 25,000 shares of our common stockissuable upon the exercise of stock options, (iii) 500,000 sharesof common stock upon conversion of Series C-3 non-voting preferredstock, and (iv) 2,250,000 shares of common stock issuable uponexercise of warrants.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|    | (8)    | Consists of (i) 294,166 shares ofour common stock, and (ii) 90,000 shares of our common stockissuable upon exercise of stock options.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|    | (9)    | Consists of 452,083 shares of ourcommon stock, and (ii) 25,000 shares of our common stock issuableupon exercise of stock options.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|         | (10)   | Consists of 321,136 shares of ourcommon stock, (ii) 25,000 shares of our common stock issuable uponexercise of stock options, (iii) 22,500 shares of our common stockissuable upon exercise of warrants, and (iv) 15,000 shares of ourcommon stock issuable upon exercise of warrants through WadeCapital Corporation Money Purchase Plan, an entity for which Mr.Lefkowitz has voting and investment control.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|         | (11)   | Consists of (i) the followingheld by our directors and executive officers (A) 3,656,232 sharesof our common stock, (B) 907,188 shares of our common stockissuable upon exercise of stock options, (C) 2,287,500 shares ofour common stock upon exercise of warrants, and (D) 500,000 sharesof our warrants upon conversion of Series C-3 non-voting preferredstock, as referenced in footnotes 3 through 10.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

|               |                     |   Amount  |  Number ofShares  |
|--------------------|--------------------------|--------------------------|-----------------------------|
| KhosoBaluch        | CEO andDirector          |  $50,000       |   104,166    |
| Robert W.Cook      | CFO                      |  $25,000       |   52,083     |
| JohnArmstrong      | ExecutiveVP              |  $10,000       |   20,833     |
| MyronKaplan        | Chairman of theBoard     |  $50,000       |   104,166    |
| JanetDillione      | Director                 |  $25,000       |   52,083     |
| GaryGelbfish       | Director                 |  $25,000       |   52,083     |
| MehmoodKhan        | Director                 |  $25,000       |   52,083     |
| Steven W.Lefkowitz | Director                 |  $65,000       |   135,416    |
|               |      |      |

|              |  2017          |  2016          |
|-------------------|--------------------------|--------------------------|
| AuditFees         |  $188,100      |  $212,700      |
| Audit RelatedFees |   5,000   |   -       |
| TaxFees           |   11,300  |   10,800  |
| All OtherFees     |   --      |   --      |
| Total             |  $204,400      |  $223,500      |

| ExhibitNumber |   |  Description ofDocument                                                                                                                                                                     |   | Registrant’sForm |   |  Dated |   | ExhibitNumber |   | FiledHerewith |
|---------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------|--------|-------------|--------|---------------|--------|---------------|
| 1.1           |   | At-the-Market Issuance Sales Agreement, dated April 8, 2015,between CorMedix Inc. and MLV.                                                                                                       |   | S-3                     |   | 4/09/2015   |   | 1.2           |   |          |
| 1.2           |   | Amendment No. 1, dated December 8, 2017, to At-the-Market IssuanceSales Agreement, dated April 8, 2015, between CorMedix Inc. and B.Riley FBR, Inc.                                              |   | 8-K                     |   | 12/08/2017  |   | 1.1           |   |          |
| 1.3           |   | Underwriting Agreement, dated April 28, 2017 by and among CorMedixInc. and H.C. Wainwright & Co., LLC.                                                                                       |   | 8-K                     |   | 5/03/2017   |   | 1.1           |   |          |
| 1.4           |   | At Market Issuance Sales Agreement, dated March 9, 2018, betweenCorMedix Inc. and B. Riley FBR, Inc.                                                                                             |   | S-3                     |   | 3/09/2018   |   | 1.1           |   |          |
| 3.1           |   | Form ofAmended and Restated Certificate of Incorporation.                                                                                                                                        |   | S-1/A                   |   | 3/01/2010   |   | 3.3           |   |          |
| 3.2           |   | Certificateof Amendment to Amended and Restated Certificate of Incorporation,dated February 24, 2010.                                                                                            |   | S-1/A                   |   | 3/19/2010   |   | 3.5           |   |          |
| 3.3           |   | Form ofAmended and Restated Bylaws as amended April 19, 2016.                                                                                                                                    |   | 10-Q                    |   | 5/10/2016   |   | 3.1           |   |          |
| 3.4           |   | Certificateof Amendment to Amended and Restated Certificate of Incorporation,dated December 3, 2012.                                                                                             |   | 10-K                    |   | 3/27/2013   |   | 3.3           |   |          |
| 3.5           |   | Certificateof Amendment to Amended and Restated Certificate of Incorporation,dated August 9, 2017.                                                                                               |   | 8-K                     |   | 8/10/2017   |   | 3.1           |   |          |
| 3.6           |   | Certificateof Designation of Series A Non-Voting Convertible Preferred Stockof CorMedix Inc., filed with the Delaware Secretary of State onFebruary 18, 2013, as corrected on February 19, 2013. |   | 8-K                     |   | 2/19/2013   |   | 3.3           |   |          |
| 3.7           |   | Certificateof Designation of Series B Non-Voting Convertible Preferred Stockof CorMedix Inc., filed with the Delaware Secretary of State onJuly 26, 2013.                                        |   | 8-K                     |   | 7/26/2013   |   | 3.4           |   |          |
| 3.8           |   | Certificateof Designation of Series C-1 Non-Voting Convertible Preferred Stockof CorMedix Inc., filed with the Delaware Secretary of State onOctober 21, 2013.                                   |   | 8-K                     |   | 10/23/2013  |   | 3.5           |   |          |
| 3.9           |   | Amendedand Restated Certificate of Designation of Series C-2 Non-VotingConvertible Preferred Stock of CorMedix Inc., filed with theDelaware Secretary of State on September 15, 2014.            |   | 8-K                     |   | 9/16/2014   |   | 3.15          |   |          |
| 3.10          |   | Amendedand Restated Certificate of Designation of Series C-3 Non-VotingConvertible Preferred Stock of CorMedix Inc., filed with theDelaware Secretary of State on September 15, 2014.            |   | 8-K                     |   | 9/16/2014   |   | 3.16          |   |          |
| 3.11          |   | Amendedand Restated Certificate of Designation of Series D Non-VotingConvertible Preferred Stock of CorMedix Inc., filed with theDelaware Secretary of State on September 15, 2014.              |   | 8-K                     |   | 9/16/2014   |   | 3.17          |   |          |

| ExhibitNumber |   | Description ofDocument                                                                                                                                                              |   |  Registrant’sForm |   | Dated  |   | ExhibitNumber  |   |  FiledHerewith |
|---------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------------|--------|-------------|--------|---------------------|--------|---------------------|
| 3.12          |   | Amendedand Restated Certificate of Designation of Series E Non-VotingConvertible Preferred Stock of CorMedix Inc., filed with theDelaware Secretary of State on September 15, 2014. |   | 8-K                           |   | 9/16/2014   |   | 3.18                |   |                |
| 3.13          |   | Amendedand Restated Certificate of Designation of Series F Non-VotingConvertible Preferred Stock of CorMedix Inc., filed with theDelaware Secretary of State on December 11, 2017.  |   | 8-K                           |   | 12/11/2017  |   | 3.1                 |   |                |
| 4.1           |   | Specimenof Common Stock Certificate.                                                                                                                                                |   | S-1/A                         |   | 3/19/2010   |   | 4.1                 |   |                |
| 4.2           |   | Form ofWarrant issued on February 19, 2013.                                                                                                                                         |   | 8-K                           |   | 2/19/2013   |   | 4.13                |   |                |
| 4.3           |   | Form ofWarrant issued to ND Partners on April 11, 2013.                                                                                                                             |   | 10-Q                          |   | 5/15/2013   |   | 4.18                |   |                |
| 4.4           |   | Form ofWarrant issued on July 30, 2013.                                                                                                                                             |   | 8-K                           |   | 7/26/2013   |   | 4.21                |   |                |
| 4.5           |   | Form ofWarrant issued on October 22, 2013.                                                                                                                                          |   | 8-K                           |   | 10/18/2013  |   | 4.22                |   |                |
| 4.6           |   | Form ofWarrant issued on January 8, 2014.                                                                                                                                           |   | 8-K                           |   | 1/09/2014   |   | 4.23                |   |                |
| 4.7           |   | Form ofWarrant issued on March 10, 2014                                                                                                                                             |   | 8-K                           |   | 03/05/2014  |   | 4.24                |   |                |
| 4.8           |   | Warrantissued March 3, 2015.                                                                                                                                                        |   | 8-K                           |   | 03/04/2015  |   | 4.1                 |   |                |
| 4.9           |   | Amendedand Restated Warrant originally issued March 24, 2010.                                                                                                                       |   | 8-K                           |   | 03/04/2015  |   | 4.3                 |   |                |
| 4.10          |   | Amendedand Restated Warrant originally issued May 30, 2013.                                                                                                                         |   | 8-K                           |   | 03/04/2015  |   | 4.2                 |   |                |
| 4.11          |   | RegistrationRights Agreement, dated March 3, 2015, by and between CorMedix Inc.and Manchester Securities Corp.                                                                      |   | 8-K                           |   | 03/04/2015  |   | 4.5                 |   |                |
| 4.12          |   | Form of Series A Warrant to Purchase Common Stock of CorMedix Inc.issued on May 3, 2017.                                                                                            |   | 8-K                           |   | 5/03/2017   |   | 4.1                 |   |                |
| 4.13          |   | Form of Series B Warrant to Purchase Common Stock of CorMedix Inc.issued on May 3, 2017.                                                                                            |   | 8-K                           |   | 5/03/2017   |   | 4.2                 |   |                |
| 4.14          |   | Form of Underwriter’s Warrant to Purchase Common Stock ofCorMedix Inc., issued May 3, 2017.                                                                                  |   | 8-K                           |   | 5/03/2017   |   | 4.3                 |   |                |
| 4.15          |   | Form of Warrant issued on November 16, 2017.                                                                                                                                        |   | 8-K                           |   | 11/13/2017  |   | 4.15                |   |                |
| 10.1*         |   | Licenseand Assignment Agreement, dated as of January 30, 2008, between theCompany and ND Partners LLC.                                                                              |   | S-1/A                         |   | 12/312009   |   | 10.5                |   |                |
| 10.2          |   | EscrowAgreement, dated as of January 30, 2008, among the Company, NDPartners LLC and the Secretary of the Company, as EscrowAgent.                                                  |   | S-1                           |   | 11/25/2009  |   | 10.6                |   |                |
| 10.3          |   | ConsultingAgreement, dated as of January 30, 2008, between the Company andFrank Prosl.                                                                                              |   | S-1                           |   | 11/25/2009  |   | 10.12               |   |                |
| 10.4          |   | Amendedand Restated 2006 Stock Incentive Plan.                                                                                                                                      |   | S-1/A                         |   | 3/01/2010   |   | 10.8                |   |                |
| 10.5          |   | Form ofIndemnification Agreement between the Company and each of itsdirectors and executive officers.                                                                               |   | S-1/A                         |   | 3/01/2010   |   | 10.17               |   |                |
| 10.6          |   | Agreementfor Work on Pharmaceutical Advertising dated January 10, 2013 byand between MKM Co-Pharma GmbH and CorMedix Inc.                                                           |   | 8-K                           |   | 1/16/2013   |   | 10.22               |   |                |

| ExhibitNumber |   | Description ofDocument                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |   |  Registrant’sForm |   | Dated  |   |  ExhibitNumber |   |  FiledHerewith |
|---------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------------|--------|-------------|--------|---------------------|--------|---------------------|
| 10.7          |   | 2013Stock Incentive Plan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   | 10-K                          |   | 3/27/2013   |   | 10.27               |   |                |
| 10.8          |   | Form ofSecurities Purchase Agreement, dated January 7, 2014, betweenCorMedix Inc. and the investors named therein.                                                                                                                                                                                                                                                                                                                                                                                                |   | 8-K                           |   | 1/09/2014   |   | 10.36               |   |                |
| 10.9          |   | PreliminaryServices Agreement dated April 8, 2015, between CorMedix Inc. and[RC]2 Pharma ConnectLLC.                                                                                                                                                                                                                                                                                                                                                                                                              |   | 10-Q                          |   | 8/06/2015   |   | 10.1                |   |                |
| 10.10         |   | Releaseof Claims and Severance Modification, dated July 17, 2015, betweenRandy Milby and CorMedix Inc.                                                                                                                                                                                                                                                                                                                                                                                                            |   | 10-K                          |   | 3/15/2016   |   | 10.16               |   |                |
| 10.11*        |   | EmploymentAgreement, dated as of September 27, 2016 and effective as ofOctober 3, 2016, between CorMedix, Inc. and KhosoBaluch                                                                                                                                                                                                                                                                                                                                                                                    |   | 8-K                           |   | 10/03/2016  |   | 10.1                |   |                |
| 10.12*        |   | EmploymentAgreement, effective February 1, 2017, between CorMedix Inc. andRobert Cook.                                                                                                                                                                                                                                                                                                                                                                                                                            |   | 10-K                          |   | 3/16/2017   |   | 10.12               |   |                |
| 10.13*        |   | EmploymentAgreement, effective February 1, 2017, between CorMedix Inc. andJudith Abrams.                                                                                                                                                                                                                                                                                                                                                                                                                          |   | 10-K                          |   | 3/16/2017   |   | 10.13               |   |                |
| 10.14         |   | EmploymentAgreement, effective March 1, 2017, between CorMedix Inc. and JohnArmstrong.                                                                                                                                                                                                                                                                                                                                                                                                                            |   | 10-K                          |   | 3/16/2017   |   | 10.14               |   |                |
| 10.15         |   | Form of Securities Purchase Agreement, dated November 17, 2017,between CorMedix Inc. and the investors signatorythereto.                                                                                                                                                                                                                                                                                                                                                                                          |   | 8-K                           |   | 11/13/2017  |   | 10.1                |   |                |
| 10.16         |   | BackstopAgreement, dated November 9, 2017, between CorMedix Inc. and theinvestor named therein.                                                                                                                                                                                                                                                                                                                                                                                                                   |   | 8-K                           |   | 11/13/2017  |   | 10.2                |   |                |
| 10.17         |   | Form ofRegistration Rights Agreement, dated November 9, 2017, by andbetween CorMedix Inc. and the investor named therein.                                                                                                                                                                                                                                                                                                                                                                                         |   | 8-K                           |   | 11/13/2017  |   | 10.3                |   |                |
| 10.18         |   | Amendment No. 1, dated as of December 11, 2017, to RegistrationRights Agreement, dated November 9, 2017, by and between CorMedixInc. and the investor named therein.                                                                                                                                                                                                                                                                                                                                              |   | 8-K                           |   | 12/11/2017  |   | 10.1                |   |                |
| 21.1          |   | List ofSubsidiaries                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   | 10-K                          |   | 3/27/2013   |   | 21.1                |   |                |
| 23.1          |   | Consentof Independent Registered Public Accounting Firm.                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   | 10-K                          |   | 3/19/2018   |   | 23.1                |   |                |
| 31.1          |   | Certificationof Principal Executive Officer pursuant to Section 302 of theSarbanes-Oxley Act of 2002.                                                                                                                                                                                                                                                                                                                                                                                                             |   |                          |   |        |   |                |   | X                   |
| 31.2          |   | Certificationof Principal Financial Officer pursuant to Section 302 of theSarbanes-Oxley Act of 2002.                                                                                                                                                                                                                                                                                                                                                                                                             |   |                          |   |        |   |                |   | X                   |
| 32.1          |   | Certificationof Principal Executive Officer pursuant to Section 906 of theSarbanes-Oxley Act of 2002.                                                                                                                                                                                                                                                                                                                                                                                                             |   | 10-K                          |   | 3/19/2018   |   | 32.1                |   |                |
| 32.2          |   | Certificationof Principal Financial Officer pursuant to Section 906 of theSarbanes-Oxley Act of 2002.                                                                                                                                                                                                                                                                                                                                                                                                             |   | 10-K                          |   | 3/19/2018   |   | 32.2                |   |                |
| 101           |   | Thefollowing materials from CorMedix Inc. Form 10-K for the year endedDecember 31, 2017, formatted in Extensible Business ReportingLanguage (XBRL): (i) Balance Sheets at December 31, 2017 and 2016,(ii) Statements of Operations for the years ended December 31, 2017and 2016, (iii) Statements of Changes in Stockholders’ Equityfor the years ended December 31, 2017 and 2016, (iv) Statements ofCash Flows for the years ended December 31, 2017 and 2016 and (v)Notes to the Financial Statements. |   | 10-K                          |   | 3/19/2018   |   | 101                 |   |                |

| * | Confidentialtreatment has been granted for portions of this document. Theomitted portions of this document have been filed separately withthe SEC.  |
|---|----------------------------------------------------------------------------------------------------------------------------------------------------------|

|          | CORMEDIXINC.    |                                               |
|---------------|-----------------|----------------------------------------------------|
|          |            |                                               |   |
| April 11,2018 | By:   | /s/KhosoBaluch                                     |   |
|          |            | KhosoBaluch                                   |   |
|          |            | Chief ExecutiveOfficer(PrincipalExecutive Officer) |   |

|          |            |                                                              |
|---------------|-----------------|-------------------------------------------------------------------|
|          |            |                                                              |   |
| April 11,2018 | By:   | /s/RobertCook                                                     |   |
|          |            | RobertCook                                                   |   |
|          |            | Chief FinancialOfficer(PrincipalFinancial and Accounting Officer) |